Chemed Corp has a consensus price target of $642 based on the ratings of 15 analysis. The 3 most-recent analyst ratings were released by RBC Capital, RBC Capital, and Oppenheimer on May 21, 2024, March 4, 2024, and February 29, 2024, respectively. With an average price target of $686.33 between RBC Capital, RBC Capital, and Oppenheimer, there's an implied 29.07% upside for Chemed Corp from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/21/2024 | Buy Now | 31.07% | RBC Capital | Ben Hendrix | $712 → $697 | Maintains | Outperform | Get Alert |
03/04/2024 | Buy Now | 33.89% | RBC Capital | Ben Hendrix | $604 → $712 | Maintains | Outperform | Get Alert |
02/29/2024 | Buy Now | 22.23% | Oppenheimer | Michael Wiederhorn | $625 → $650 | Maintains | Outperform | Get Alert |
01/17/2024 | Buy Now | 17.53% | Oppenheimer | Michael Wiederhorn | $590 → $625 | Maintains | Outperform | Get Alert |
10/30/2023 | Buy Now | 13.58% | RBC Capital | Ben Hendrix | $576 → $604 | Maintains | Outperform | Get Alert |
07/31/2023 | Buy Now | 8.32% | RBC Capital | Ben Hendrix | $610 → $576 | Maintains | Outperform | Get Alert |
07/27/2023 | Buy Now | 10.95% | Oppenheimer | Michael Wiederhorn | $610 → $590 | Maintains | Outperform | Get Alert |
05/01/2023 | Buy Now | 14.71% | RBC Capital | Ben Hendrix | $587 → $610 | Maintains | Outperform | Get Alert |
04/28/2023 | Buy Now | 14.71% | Oppenheimer | Michael Wiederhorn | $580 → $610 | Maintains | Outperform | Get Alert |
02/27/2023 | Buy Now | 10.39% | RBC Capital | Ben Hendrix | $545 → $587 | Maintains | Outperform | Get Alert |
11/03/2022 | Buy Now | 2.49% | RBC Capital | Ben Hendrix | $541 → $545 | Maintains | Outperform | Get Alert |
08/01/2022 | Buy Now | 1.74% | RBC Capital | Ben Hendrix | $592 → $541 | Maintains | Outperform | Get Alert |
04/28/2022 | Buy Now | 11.33% | RBC Capital | Ben Hendrix | $579 → $592 | Maintains | Outperform | Get Alert |
03/04/2022 | Buy Now | 8.88% | RBC Capital | Frank Morgan | $609 → $579 | Maintains | Outperform | Get Alert |
07/29/2021 | Buy Now | 14.52% | RBC Capital | Frank Morgan | — | Maintains | Outperform | Get Alert |
The latest price target for Chemed (NYSE:CHE) was reported by RBC Capital on May 21, 2024. The analyst firm set a price target for $697.00 expecting CHE to rise to within 12 months (a possible 30.46% upside). 7 analyst firms have reported ratings in the last year.
The latest analyst rating for Chemed (NYSE:CHE) was provided by RBC Capital, and Chemed maintained their outperform rating.
There is no last upgrade for Chemed
There is no last downgrade for Chemed.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Chemed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Chemed was filed on May 21, 2024 so you should expect the next rating to be made available sometime around May 21, 2025.
While ratings are subjective and will change, the latest Chemed (CHE) rating was a maintained with a price target of $712.00 to $697.00. The current price Chemed (CHE) is trading at is $534.27, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.